免疫学sci有哪些期刊

分类：SCI相关知识 时间：2023-11-07 10:52 关注：(1)

　　免疫学sci有哪些期刊？关于免疫学类的sci期刊有很多的， 很多作者不知道怎么选择期刊投稿，要根据论文的内容，选择符合的刊物投稿。免疫学类sci论文就要选择相关的刊物投稿，接下来，详细的推荐几本期刊，仅供参考。

　　1、IMMUNOLOGY

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：2区

　　期刊简介：Immunology is one of the longest-established immunology journals and is recognised as one of the leading journals in its field. We have global representation in authors, editors and reviewers.

　　2、Vaccines

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：3区

　　期刊简介：Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in open access form in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

　　3、IMMUNOBIOLOGY

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：4区

　　期刊简介：Immunobiology is a peer-reviewed journal that publishes highly innovative research approaches for a wide range of immunological subjects, including

　　• Innate Immunity,

　　• Adaptive Immunity,

　　• Complement Biology,

　　• Macrophage and Dendritic Cell Biology,

　　• Parasite Immunology,

　　• Tumour Immunology,

　　4、OncoImmunology

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：2区

　　期刊简介：Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.